The European biotech, which is not being named by OctoPlus, will become the seventh company that the drug delivery specialist has worked on a controlled release formulation for.
Under the terms of the latest agreement OctoPlus will asses the feasibility of creating a formulation of the client’s active pharmaceutical ingredient (API) using its drug delivery technology.
If the evaluation deems that a formulation could be created the contract may be extended to become a full process development, manufacturing and licensing agreement.
